A financing announcement is usually an invitation to admire a number. On May 9, 2024, R3 Vascular supplied one: $87 million. Tucked beside it was a change in the working life of its founder, Kamal Ramzipoor. Christopher M. Owens would become president and chief executive. Ramzipoor would become chief technology officer. The company had more money, a new CEO and a founder whose next assignment put technology explicitly back in his title.
There is a familiar temptation to read an executive handover as a verdict. This one is more interesting when read as a division of work. Ramzipoor had already spent years moving between development, manufacturing and management. The engineering and the organization had grown up together. His career provides a useful view of what happens when the person who helps build a business continues inside it after the chief executive’s chair changes occupants.
The letters on the business card changed. The accumulated experience came with him.
The other side of the handover
At R3, the 2024 financing and appointments arrived in the same announcement. Affiliates of Deerfield Management led the round, with participation from existing shareholders including 415 Capital and a strategic investor. That combination made the transition a practical business event: fresh capital and a different allocation of leadership responsibilities, announced together.
Ramzipoor remained the founder. Owens took responsibility as president and CEO. A technical leadership role gave the organization a named place for the founder’s continuing work. Nothing about that arrangement requires a theory about private ambition. The publicly visible change is sufficient: the company retained him and assigned him the technology brief.
To understand why that brief fits, it helps to leave the funding announcement for a while. Long before R3, Ramzipoor had worked in engineering and research and development at companies including Guidant, Progressive Angioplasty Systems and Acuson. He also held the combined responsibilities of chief technology officer and vice president of R&D at Micrus Endovascular, followed by a director role at Boston Scientific. Management and technical work were already sharing a desk.
A company with two shores
Amaranth Medical supplies an earlier chapter in that overlap. Ramzipoor co-founded the company and went on to lead it. Its story brought together California industry experience and materials expertise in Singapore. The university collaborators were professors Freddy Boey and Subbu Venkatraman of Nanyang Technological University. These were named people with distinct expertise, a more useful beginning than the conveniently solitary founder of business folklore.
In June 2015, Singapore minister S Iswaran highlighted their collaboration at the International Conference on Materials for Advanced Technologies. He described Amaranth as emerging from the connection between Ramzipoor and the two polymer experts. In a speech concerned with the economic value of research, the company provided a concrete example of academic knowledge becoming an industrial undertaking.
The geography extended into the organization. Amaranth had research and manufacturing operations in Singapore and at its Silicon Valley headquarters. A company spread across those locations has more to coordinate than a promising experiment. Research must communicate with manufacturing; a technical decision must survive being explained, repeated and implemented by other people. Collaboration acquires calendars, budgets and operating responsibilities.
That setting helps explain the breadth of Ramzipoor’s job. In October 2013, Amaranth identified him as general manager and chief technical officer. By its January 2014 investment announcement, it identified him as CEO. Those titles put both the commercial organization and the underlying technical work into the same short stretch of his biography.
The money had to last
Amaranth’s October 2013 Series B brought in $20 million. DCP Management of Singapore led the round; existing investors included Bio*One Capital, Charter Life Sciences and Phillip Capital, while Venstar Capital also participated. The financing placed Ramzipoor in the familiar founder’s position of having to connect technical work with the confidence of people paying for it.
His comments that month were unusually useful for understanding the business side of his work. In an interview, he discussed operating on a tight budget and the importance of demonstrating how funding would be used. The remark was about stewardship, a subject that rarely receives the typographical enthusiasm given to the size of a round.
“Investors look at how the funding is managed and how it can be stretched.”
Kamal Ramzipoor · 2013
There is an engineer’s practicality in that observation, though the arithmetic belongs to any founder. Capital buys a finite amount of work. How a company organizes that work affects how far it can proceed before it must ask again. Ramzipoor was speaking about the management of the money, including the reassurance that careful use could give investors.
January 2014 brought another connection: Boston Scientific invested in Amaranth. Ramzipoor had previously worked at Boston Scientific. The sequence is a distinctive part of his career, placing a former employer on the investor side of a company he led. It also shows how a professional history can return in a different form. The organization’s role had changed; Ramzipoor was now speaking for the smaller business.
Small decisions, long calendars
The executive titles tell only part of this story. The technical record supplies names, dates and very particular problems. Ramzipoor appears as a co-inventor with Alfred N. K. Chia and Liwei Wang on a patent concerning tubular casting processes. Its filing history reaches back well before its 2020 grant. The document belongs to a different calendar from the funding announcement: years of development and paperwork attached to a manufacturing method.
Its subject is process control. The described method addresses such variables as immersion time, intervals between steps, drying and withdrawal rates. These are the sorts of decisions that can disappear inside a finished object. Yet they help determine what material is actually produced. A design has to be made, and made with the intended properties. Manufacturing gives every elegant drawing an appointment with reality.
Another application published in January 2025 names Ramzipoor and Richard J. Saunders as inventors. It concerns a composite structure and the relationship between its components, including how they permit movement relative to one another. The applicant is Razmodics LLC. That identification matters when reading the record: an inventor’s name connects the work to a person, while the applicant names the organization attached to that application.
Chang Y. Lee is another recurring collaborator. A European patent specification published in March 2024 names both Lee and Ramzipoor. Across these records, invention appears as a shared activity with a trail of contributors. The names prevent an executive profile from quietly assigning an entire technical enterprise to its most visible individual.
Two dates in the history of US10646359B2: May 21, 2012 and May 12, 2020. One document, a much longer working calendar.
Back in the technical chair
R3 announced Ramzipoor’s appointment as CEO in October 2020, alongside a Series A consisting of $15 million in new equity and the conversion of $2.8 million in notes. Jack Springer, the executive chairman, described him as a hands-on leader. The appointment connected an experienced company builder with a business still assembling the resources for its next phase.
The amount is worth reading precisely. The disclosed total was $17.8 million, and part of it represented converted notes. Four years later, the Series B was $87 million. These are separate financing events; they are useful landmarks in the organization’s development. They also bracket Ramzipoor’s publicly announced R3 CEO chapter, before the move to CTO.
In 2026, the organization around him continued to change. August brought Robert Spanos in global market development and Katie Segreto in finance. In September, Lisa Wipperman Heine joined the board. The additions put further commercial, financial and board experience around the technology team. They offer a visible picture of a business distributing work among more specialists.
For a founder with Ramzipoor’s background, that organizational context is part of the story. A technical role sits among other responsibilities: financing, market development, operations and governance. A company has to make those functions work together. The CTO title locates one contribution inside that arrangement, while the founder designation preserves the connection to its beginnings.
The work that survives a title
Ramzipoor’s career is easiest to follow through those connections. At Amaranth, university researchers and an industry executive helped create a company with operations on two shores. Investors financed the next work. Patent documents recorded collaborators and manufacturing questions. At R3, a financing announcement marked another change in responsibility.
The continuity lies in the passage between technical ideas and the organizations built to develop them. Ramzipoor has occupied several positions along that passage. General manager, technical chief, CEO, founder and CTO are all part of the documented sequence. Reading the titles together gives a fuller picture than allowing any one of them to stand for the whole person’s professional life.
In 2013, he spoke about making funding stretch. In 2024, he took a new technical assignment at the company he founded. Between the two sits the less photogenic substance of a career: colleagues, processes, financing and repeated changes in responsibility. The next business card was short. The work behind it had taken years.